Oct 2026· Cancers· Vol 18, pp. 3181· 0 citations· 141 references
Medicine
TL;DR
This review summarizes the current landscape of individual prognostic biomarkers in TNBC and further emphasizes the transition toward promising multi-prognostic biomarker panels for effectively capturing the biological complexity of TNBC and enabling more personalized therapeutic interventions.
Abstract
Simple Summary Triple-negative breast cancer (TNBC) is an aggressive and highly heterogeneous form of breast cancer marked by substantial risks of recurrence and metastasis. Unlike other subtypes of breast cancer, TNBC does not possess the three critical molecular traits that can act as key therapeutic targets for classification, necessitating the need for identification of reliable prognostic markers. However, the complex heterogeneity of TNBC has led to significant discrepancies in the prognostic value of individual biomarkers. This review summarizes the current landscape of individual prognostic biomarkers in TNBC and further emphasizes the transition toward promising multi-prognostic biomarker panels. We aim to highlight the need for such integrated prognostic approaches for effectively capturing the biological complexity of TNBC and thereby enabling more personalized therapeutic interventions.
Multibiomarker integration, supported by prospective validation and automated models, represents a promising approach to personalize treatment algorithms in early-stage TNBC, balancing efficacy and toxicity while guiding escalation and de-escalation strategies.
Federica Falcone, Erica Pietroluongo, P. De Placido· Current Opinion in Oncology· 0 citations
Simple Summary Triple-negative breast cancer (TNBC) is an aggressive and clinically complex form of breast cancer that presents substantial challenges in diagnosis, treatment, and long-term management. This review discusses the major clinical challenges associated with TNBC, together with the currently available treatm...
Breast cancer is one of the most commonly diagnosed malignancies among women worldwide and is frequently curable when identified at an early stage. However, advanced and metastatic disease continue to account for a substantial proportion of breast cancer-related deaths, particularly among patients with aggressive subty...
Shayla Murray, M. Becker, B. Lim· Frontiers in Oncology· 0 citations
Triple-negative breast cancer (TNBC) is an aggressive malignancy with limited therapeutic options and a high risk of relapse and mortality. Consequently, there is a critical need for personalized treatment strategies that reflect the unique biology, clonal architecture, and evolutionary dynamics of individual tumors. H...
P. Victori, Kui Hua, Alecia-Jane Twigger et al.· Cell Reports Medicine· 0 citations
It is revealed that obesity is associated with coordinated immune-metabolic remodeling in TNBC, characterized by checkpoint enrichment and lipid dysregulation, which may help explain the enhanced anti-PD-1 responsiveness and should be taken into account in the field of precision medicine.
P. Ji, Huai-Liang Wu, Li-Huan He et al.· Cancer Letters· 0 citations
Abstract In the personalized management of stage II colorectal cancer (CRC), traditional TNM (Tumor, Node, Metastasis) staging has limited ability to accurately stratify the risk of postoperative recurrence. Consequently, oncologists frequently face a major therapeutic dilemma when determining the use of adjuvant chemo...
Ying-Nan Liu, Ben-gang Wang, Qian Xu· The Journal of Pathology: Cl...· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.
